KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Change in Account Payables (2017 - 2025)

Bionano Genomics' Change in Account Payables history spans 7 years, with the latest figure at -$254000.0 for Q3 2025.

  • For Q3 2025, Change in Account Payables fell 719.35% year-over-year to -$254000.0; the TTM value through Sep 2025 reached -$2.7 million, up 55.33%, while the annual FY2024 figure was -$3.4 million, 71.43% down from the prior year.
  • Change in Account Payables for Q3 2025 was -$254000.0 at Bionano Genomics, up from -$318000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.1 million in Q3 2021 and bottomed at -$4.4 million in Q4 2023.
  • The 5-year median for Change in Account Payables is -$254000.0 (2025), against an average of $123263.2.
  • The largest annual shift saw Change in Account Payables surged 669.11% in 2021 before it crashed 719.35% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $1.8 million in 2021, then soared by 73.31% to $3.2 million in 2022, then tumbled by 238.15% to -$4.4 million in 2023, then surged by 60.4% to -$1.7 million in 2024, then soared by 85.41% to -$254000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Change in Account Payables are -$254000.0 (Q3 2025), -$318000.0 (Q2 2025), and -$401000.0 (Q1 2025).